Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?
ATI(N) classification system
Alzheimer’s disease
Astrocytes
Biomarkers
Clinical trials
GFAP
Longitudinal studies
Microglia
Neuroinflammation
YKL-40
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
29
05
2024
accepted:
28
06
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
31
7
2024
Statut:
epublish
Résumé
Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with a significant risk of serious adverse events. Thus, it seems crucial to explore complementary therapeutic approaches. Genome-wide association studies identified robust associations between AD and several AD risk genes related to immune response, including but not restricted to CD33 and TREM2. Here, we critically reviewed the current knowledge on candidate neuroinflammatory biomarkers and their role in characterizing the pathophysiology of AD. Neuroinflammation is recognized to be a crucial and contributing component of AD pathogenesis. The fact that neuroinflammation is most likely present from earliest pre-stages of AD and co-occurs with the deposition of Aβ reinforces the need to precisely define the sequence and nature of neuroinflammatory events. Numerous clinical trials involving anti-inflammatory drugs previously yielded unfavorable outcomes in early and mild-to-moderate AD. Although the reasons behind these failures remain unclear, these may include the time and the target selected for intervention. Indeed, in our review, we observed a stage-dependent neuroinflammatory process in the AD brain. While the initial activation of glial cells counteracts early brain Aβ deposition, the downregulation in the functional state of microglia occurs at more advanced disease stages. To address this issue, personalized neuroinflammatory modulation therapy is required. The emergence of reliable blood-based neuroinflammatory biomarkers, particularly glial fibrillary acidic protein, a marker of reactive astrocytes, may facilitate the classification of AD patients based on the ATI(N) biomarker framework. This expands upon the traditional classification of Aβ ("A"), tau ("T"), and neurodegeneration ("N"), by incorporating a novel inflammatory component ("I"). The present review outlines the current knowledge on potential neuroinflammatory biomarkers and, importantly, emphasizes the role of longitudinal analyses, which are needed to accurately monitor the dynamics of cerebral inflammation. Such a precise information on time and place will be required before anti-inflammatory therapeutic interventions can be considered for clinical evaluation. We propose that an effective anti-neuroinflammatory therapy should specifically target microglia and astrocytes, while considering the individual ATI(N) status of patients.
Sections du résumé
BACKGROUND
BACKGROUND
Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with a significant risk of serious adverse events. Thus, it seems crucial to explore complementary therapeutic approaches. Genome-wide association studies identified robust associations between AD and several AD risk genes related to immune response, including but not restricted to CD33 and TREM2. Here, we critically reviewed the current knowledge on candidate neuroinflammatory biomarkers and their role in characterizing the pathophysiology of AD.
MAIN BODY
METHODS
Neuroinflammation is recognized to be a crucial and contributing component of AD pathogenesis. The fact that neuroinflammation is most likely present from earliest pre-stages of AD and co-occurs with the deposition of Aβ reinforces the need to precisely define the sequence and nature of neuroinflammatory events. Numerous clinical trials involving anti-inflammatory drugs previously yielded unfavorable outcomes in early and mild-to-moderate AD. Although the reasons behind these failures remain unclear, these may include the time and the target selected for intervention. Indeed, in our review, we observed a stage-dependent neuroinflammatory process in the AD brain. While the initial activation of glial cells counteracts early brain Aβ deposition, the downregulation in the functional state of microglia occurs at more advanced disease stages. To address this issue, personalized neuroinflammatory modulation therapy is required. The emergence of reliable blood-based neuroinflammatory biomarkers, particularly glial fibrillary acidic protein, a marker of reactive astrocytes, may facilitate the classification of AD patients based on the ATI(N) biomarker framework. This expands upon the traditional classification of Aβ ("A"), tau ("T"), and neurodegeneration ("N"), by incorporating a novel inflammatory component ("I").
CONCLUSIONS
CONCLUSIONS
The present review outlines the current knowledge on potential neuroinflammatory biomarkers and, importantly, emphasizes the role of longitudinal analyses, which are needed to accurately monitor the dynamics of cerebral inflammation. Such a precise information on time and place will be required before anti-inflammatory therapeutic interventions can be considered for clinical evaluation. We propose that an effective anti-neuroinflammatory therapy should specifically target microglia and astrocytes, while considering the individual ATI(N) status of patients.
Identifiants
pubmed: 39080712
doi: 10.1186/s12974-024-03163-y
pii: 10.1186/s12974-024-03163-y
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
187Informations de copyright
© 2024. The Author(s).
Références
Kumar A, Sidhu J, Goyal A, Tsao JW. Alzheimer Disease. In StatPearls. 2023.
Chávez-Fumagalli MA, Shrivastava P, Aguilar-Pineda JA, Nieto-Montesinos R, Del-Carpio GD, Peralta-Mestas A, Caracela-Zeballos C, Valdez-Lazo G, Fernandez-Macedo V, Pino-Figueroa A, et al. Diagnosis of Alzheimer’s disease in developed and developing countries: systematic review and meta-analysis of diagnostic test accuracy. J Alzheimers Dis Rep. 2021;5:15–30.
pubmed: 33681713
pmcid: 7902992
doi: 10.3233/ADR-200263
Dhillon S. Aducanumab: first approval. Drugs. 2021;81:1437–43.
pubmed: 34324167
doi: 10.1007/s40265-021-01569-z
Reardon S. FDA approves Alzheimer’s drug lecanemab amid safety concerns. Nature. 2023;613:227–8.
pubmed: 36627422
doi: 10.1038/d41586-023-00030-3
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, et al. Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512–27.
pubmed: 37459141
pmcid: 10352931
doi: 10.1001/jama.2023.13239
Melchiorri D, Merlo S, Micallef B, Borg JJ, Dráfi F. Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy? Front Pharmacol. 2023;14:1196413.
pubmed: 37332353
pmcid: 10272781
doi: 10.3389/fphar.2023.1196413
Imbimbo BP, Ippati S, Watling M, Balducci C. A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. Alzheimers Dement. 2022;18:1008–37.
pubmed: 34533272
doi: 10.1002/alz.12453
Lozupone M, Imbimbo BP, Balducci C, Lo Vecchio F, Bisceglia P, Latino RR, Leone M, Dibello V, Solfrizzi V, Greco A, et al. Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer’s disease? Alzheimers Dement. 2023;19:353–68.
pubmed: 35900209
doi: 10.1002/alz.12728
Venkataraman AV, Mansur A, Rizzo G, Bishop C, Lewis Y, Kocagoncu E, Lingford-Hughes A, Huiban M, Passchier J, Rowe JB, et al. Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer’s disease. Sci Transl Med. 2022;14:eabk1051.
pubmed: 35976998
doi: 10.1126/scitranslmed.abk1051
Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL. Synaptic degeneration in Alzheimer disease. Nat Rev Neurol. 2023;19:19–38.
pubmed: 36513730
doi: 10.1038/s41582-022-00749-z
Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation. 2004;1:14.
pubmed: 15285801
pmcid: 509427
doi: 10.1186/1742-2094-1-14
Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer’s disease drug development pipeline: 2024. Alzheimers Dement (N Y). 2024;10: e12465.
pubmed: 38659717
doi: 10.1002/trc2.12465
Morgan DG, Mielke MM. Knowledge gaps in Alzheimer’s disease immune biomarker research. Alzheimers Dement. 2021;17:2030–42.
pubmed: 33984178
doi: 10.1002/alz.12342
Blennow K, Galasko D, Perneczky R, Quevenco FC, van der Flier WM, Akinwonmi A, Carboni M, Jethwa A, Suridjan I, Zetterberg H. The potential clinical value of plasma biomarkers in Alzheimer’s disease. Alzheimers Dement. 2023.
Barthélemy NR, Salvadó G, Schindler SE, He Y, Janelidze S, Collij LE, Saef B, Henson RL, Chen CD, Gordon BA, et al. Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med. 2024;30:1085–95.
pubmed: 38382645
pmcid: 11031399
doi: 10.1038/s41591-024-02869-z
Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, Langhough RE, Cody K, Wilson R, Carlsson CM, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 2024;81:255–63.
pubmed: 38252443
pmcid: 10804282
doi: 10.1001/jamaneurol.2023.5319
Malek-Ahmadi M, Su Y, Ghisays V, Luo J, Devadas V, Chen Y, Lee W, Protas H, Chen K, Zetterberg H, et al. Plasma NfL is associated with the APOE ε4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults. Alzheimers Res Ther. 2023;15:74.
pubmed: 37038190
pmcid: 10084600
doi: 10.1186/s13195-023-01221-w
Rosenberg A, Öhlund-Wistbacka U, Hall A, Bonnard A, Hagman G, Rydén M, Thunborg C, Wiggenraad F, Sandebring-Matton A, Solomon A, Kivipelto M. β-Amyloid, tau, neurodegeneration classification and eligibility for anti-amyloid treatment in a memory clinic population. Neurology. 2022;99:e2102–13.
pubmed: 36130840
pmcid: 9651451
doi: 10.1212/WNL.0000000000201043
Imbimbo BP, Watling M, Imbimbo C, Nisticò R. Plasma ATN(I) classification and precision pharmacology in Alzheimer’s disease. Alzheimers Dement. 2023;19:4729–34.
pubmed: 37079778
doi: 10.1002/alz.13084
Gaetani L, Paolini Paoletti F, Bellomo G, Mancini A, Simoni S, Di Filippo M, Parnetti L. CSF and blood biomarkers in neuroinflammatory and neurodegenerative diseases: implications for treatment. Trends Pharmacol Sci. 2020;41:1023–37.
pubmed: 33127098
doi: 10.1016/j.tips.2020.09.011
Liu Y, Shen X, Zhang Y, Zheng X, Cepeda C, Wang Y, Duan S, Tong X. Interactions of glial cells with neuronal synapses, from astrocytes to microglia and oligodendrocyte lineage cells. Glia. 2023;71:1383–401.
pubmed: 36799296
doi: 10.1002/glia.24343
Huffels CFM, Middeldorp J, Hol EM. Aß pathology and neuron-glia interactions: a synaptocentric view. Neurochem Res. 2023;48:1026–46.
pubmed: 35976488
doi: 10.1007/s11064-022-03699-6
Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM. Microglial genes regulating neuroinflammation in the progression of Alzheimer’s disease. Curr Opin Neurobiol. 2016;36:74–81.
pubmed: 26517285
doi: 10.1016/j.conb.2015.10.004
Jensen CJ, Massie A, De Keyser J. Immune players in the CNS: the astrocyte. J Neuroimmune Pharmacol. 2013;8:824–39.
pubmed: 23821340
doi: 10.1007/s11481-013-9480-6
Jiwaji Z, Tiwari SS, Avilés-Reyes RX, Hooley M, Hampton D, Torvell M, Johnson DA, McQueen J, Baxter P, Sabari-Sankar K, et al. Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology. Nat Commun. 2022;13:135.
pubmed: 35013236
pmcid: 8748982
doi: 10.1038/s41467-021-27702-w
Wang S, Colonna M. Microglia in Alzheimer’s disease: a target for immunotherapy. J Leukoc Biol. 2019;106:219–27.
pubmed: 30725482
doi: 10.1002/JLB.MR0818-319R
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405.
pubmed: 25792098
pmcid: 5909703
doi: 10.1016/S1474-4422(15)70016-5
Forloni G, Balducci C. Alzheimer’s disease, oligomers, and inflammation. J Alzheimers Dis. 2018;62:1261–76.
pubmed: 29562537
pmcid: 5869993
doi: 10.3233/JAD-170819
Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques. Nat Commun. 2015;6:6176.
pubmed: 25630253
doi: 10.1038/ncomms7176
Cai Y, Liu J, Wang B, Sun M, Yang H. Microglia in the neuroinflammatory pathogenesis of Alzheimer’s disease and related therapeutic targets. Front Immunol. 2022;13: 856376.
pubmed: 35558075
pmcid: 9086828
doi: 10.3389/fimmu.2022.856376
Merlo S, Spampinato SF, Caruso GI, Sortino MA. The ambiguous role of microglia in Aβ toxicity: chances for therapeutic intervention. Curr Neuropharmacol. 2020;18:446–55.
pubmed: 32003695
pmcid: 7457435
doi: 10.2174/1570159X18666200131105418
Sims R, Hill M, Williams J. The multiplex model of the genetics of Alzheimer’s disease. Nat Neurosci. 2020;23:311–22.
pubmed: 32112059
doi: 10.1038/s41593-020-0599-5
Hampel H, Caraci F, Cuello AC, Caruso G, Nisticò R, Corbo M, Baldacci F, Toschi N, Garaci F, Chiesa PA, et al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer’s disease. Front Immunol. 2020;11:456.
pubmed: 32296418
pmcid: 7137904
doi: 10.3389/fimmu.2020.00456
Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78:631–43.
pubmed: 23623698
pmcid: 3706457
doi: 10.1016/j.neuron.2013.04.014
Rathore N, Ramani SR, Pantua H, Payandeh J, Bhangale T, Wuster A, Kapoor M, Sun Y, Kapadia SB, Gonzalez L, et al. Paired Immunoglobulin-like Type 2 Receptor Alpha G78R variant alters ligand binding and confers protection to Alzheimer’s disease. PLoS Genet. 2018;14: e1007427.
pubmed: 30388101
pmcid: 6235402
doi: 10.1371/journal.pgen.1007427
Lu L, Yao QY, Ruan SS, Hu JW, Long WJ, Dai WZ, Ma T, Zhu XC. Explore the role of CR1 genetic variants in late-onset Alzheimer’s disease susceptibility. Psychiatr Genet. 2021;31:216–29.
pubmed: 34347684
doi: 10.1097/YPG.0000000000000291
Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, Li Z, Del-Aguila JL, Dube U, Farias FG, et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer’s disease risk. Sci Transl Med. 2019; 11.
Liu X, Che R, Liang W, Zhang Y, Wu L, Han C, Lu H, Song W, Wu Y, Wang Z. Clusterin transduces Alzheimer-risk signals to amyloidogenesis. Signal Transduct Target Ther. 2022;7:325.
pubmed: 36138003
pmcid: 9499966
doi: 10.1038/s41392-022-01157-x
De Roeck A, Van Broeckhoven C, Sleegers K. The role of ABCA7 in Alzheimer’s disease: evidence from genomics, transcriptomics and methylomics. Acta Neuropathol. 2019;138:201–20.
pubmed: 30903345
pmcid: 6660495
doi: 10.1007/s00401-019-01994-1
Owens HA, Thorburn LE, Walsby E, Moon OR, Rizkallah P, Sherwani S, Tinsley CL, Rogers L, Cerutti C, Ridley AJ, et al. Alzheimer’s disease-associated P460L variant of EphA1 dysregulates receptor activity and blood-brain barrier function. Alzheimers Dement. 2024;20:2016–33.
pubmed: 38184788
pmcid: 10984439
doi: 10.1002/alz.13603
James LM, Christova P, Lewis SM, Engdahl BE, Georgopoulos A, Georgopoulos AP. Protective effect of human leukocyte antigen (HLA) Allele DRB1*13:02 on age-related brain gray matter volume reduction in healthy women. EBioMedicine. 2018;29:31–7.
pubmed: 29452862
pmcid: 5925575
doi: 10.1016/j.ebiom.2018.02.005
Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol. 2006;7:1266–73.
pubmed: 17110943
doi: 10.1038/ni1411
Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell. 2017;169:1276-1290.e1217.
pubmed: 28602351
doi: 10.1016/j.cell.2017.05.018
Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Piña-Crespo JC, Zhang M, et al. TREM2 is a receptor for β-amyloid that mediates microglial function. Neuron. 2018;97:1023-1031.e1027.
pubmed: 29518356
pmcid: 5889092
doi: 10.1016/j.neuron.2018.01.031
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368:117–27.
pubmed: 23150934
doi: 10.1056/NEJMoa1211851
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368:107–16.
pubmed: 23150908
doi: 10.1056/NEJMoa1211103
Li JT, Zhang Y. TREM2 regulates innate immunity in Alzheimer’s disease. J Neuroinflammation. 2018;15:107.
pubmed: 29655369
pmcid: 5899410
doi: 10.1186/s12974-018-1148-y
Zheng H, Cheng B, Li Y, Li X, Chen X, Zhang YW. TREM2 in Alzheimer’s disease: microglial survival and energy metabolism. Front Aging Neurosci. 2018;10:395.
pubmed: 30532704
pmcid: 6265312
doi: 10.3389/fnagi.2018.00395
Hickman SE, El Khoury J. TREM2 and the neuroimmunology of Alzheimer’s disease. Biochem Pharmacol. 2014;88:495–8.
pubmed: 24355566
doi: 10.1016/j.bcp.2013.11.021
Carmona S, Zahs K, Wu E, Dakin K, Bras J, Guerreiro R. The role of TREM2 in Alzheimer’s disease and other neurodegenerative disorders. Lancet Neurol. 2018;17:721–30.
pubmed: 30033062
doi: 10.1016/S1474-4422(18)30232-1
Ruiz A, Dols-Icardo O, Bullido MJ, Pastor P, Rodríguez-Rodríguez E, López de Munain A, de Pancorbo MM, Pérez-Tur J, Alvarez V, Antonell A, et al. Assessing the role of the TREM2 pR47H variant as a risk factor for Alzheimer’s disease and frontotemporal dementia. Neurobiol Aging. 2014;35:444.
doi: 10.1016/j.neurobiolaging.2013.08.011
Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J, Engelborghs S, Vandenbulcke M, Van Dongen J, Geerts N, et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer’s disease and frontotemporal dementia. Neurobiol Aging. 2014;35(726):e711-729.
Condello C, Yuan P, Grutzendler J. Microglia-mediated neuroprotection, TREM2, and Alzheimer’s disease: evidence from optical imaging. Biol Psychiatry. 2018;83:377–87.
pubmed: 29169609
doi: 10.1016/j.biopsych.2017.10.007
Cheng-Hathaway PJ, Reed-Geaghan EG, Jay TR, Casali BT, Bemiller SM, Puntambekar SS, von Saucken VE, Williams RY, Karlo JC, Moutinho M, et al. The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer’s disease. Mol Neurodegener. 2018;13:29.
pubmed: 29859094
pmcid: 5984804
doi: 10.1186/s13024-018-0262-8
Li R, Wang X, He P. The most prevalent rare coding variants of TREM2 conferring risk of Alzheimer’s disease: a systematic review and meta-analysis. Exp Ther Med. 2021;21:347.
pubmed: 33732320
pmcid: 7903442
doi: 10.3892/etm.2021.9778
Slattery CF, Beck JA, Harper L, Adamson G, Abdi Z, Uphill J, Campbell T, Druyeh R, Mahoney CJ, Rohrer JD, et al. R47H TREM2 variant increases risk of typical early-onset Alzheimer’s disease but not of prion or frontotemporal dementia. Alzheimers Dement. 2014;10:602-608.e604.
pubmed: 25160042
doi: 10.1016/j.jalz.2014.05.1751
Jin SC, Carrasquillo MM, Benitez BA, Skorupa T, Carrell D, Patel D, Lincoln S, Krishnan S, Kachadoorian M, Reitz C, et al. TREM2 is associated with increased risk for Alzheimer’s disease in African Americans. Mol Neurodegener. 2015;10:19.
pubmed: 25886450
pmcid: 4426167
doi: 10.1186/s13024-015-0016-9
Miyashita A, Wen Y, Kitamura N, Matsubara E, Kawarabayashi T, Shoji M, Tomita N, Furukawa K, Arai H, Asada T, et al. Lack of genetic association between TREM2 and late-onset Alzheimer’s disease in a Japanese population. J Alzheimers Dis. 2014;41:1031–8.
pubmed: 24762945
doi: 10.3233/JAD-140225
Huang M, Wang D, Xu Z, Xu Y, Xu X, Ma Y, Xia Z. Lack of genetic association between TREM2 and Alzheimer’s disease in East Asian population: a systematic review and meta-analysis. Am J Alzheimers Dis Other Demen. 2015;30:541–6.
pubmed: 25852195
pmcid: 10852690
doi: 10.1177/1533317515577128
Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, Kunkle BW, Boland A, Raybould R, Bis JC, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. Nat Genet. 2017;49:1373–84.
pubmed: 28714976
pmcid: 5669039
doi: 10.1038/ng.3916
Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, et al. Coding variants in TREM2 increase risk for Alzheimer’s disease. Hum Mol Genet. 2014;23:5838–46.
pubmed: 24899047
pmcid: 4189899
doi: 10.1093/hmg/ddu277
Ulland TK, Song WM, Huang SC, Ulrich JD, Sergushichev A, Beatty WL, Loboda AA, Zhou Y, Cairns NJ, Kambal A, et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell. 2017;170:649-663.e613.
pubmed: 28802038
pmcid: 5573224
doi: 10.1016/j.cell.2017.07.023
Schlepckow K, Kleinberger G, Fukumori A, Feederle R, Lichtenthaler SF, Steiner H, Haass C. An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function. EMBO Mol Med. 2017;9:1356–65.
pubmed: 28855300
pmcid: 5623859
doi: 10.15252/emmm.201707672
Jiang T, Tan L, Chen Q, Tan MS, Zhou JS, Zhu XC, Lu H, Wang HF, Zhang YD, Yu JT. A rare coding variant in TREM2 increases risk for Alzheimer’s disease in Han Chinese. Neurobiol Aging. 2016;42(217):e211-213.
Jiang T, Hou JK, Gao Q, Yu JT, Zhou JS, Zhao HD, Zhang YD. TREM2 p.H157Y variant and the risk of Alzheimer’s disease: a meta-analysis involving 14,510 subjects. Curr Neurovasc Res. 2016;13:318–20.
pubmed: 27501831
doi: 10.2174/1567202613666160808095530
Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, Öhrfelt A, Blennow K, Hardy J, Schott J, et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease. Mol Neurodegener. 2016;11:3.
pubmed: 26754172
pmcid: 4709982
doi: 10.1186/s13024-016-0071-x
Piccio L, Deming Y, Del-Águila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, Borroni B, Cruchaga C. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol. 2016;131:925–33.
pubmed: 26754641
pmcid: 4867123
doi: 10.1007/s00401-016-1533-5
Suárez-Calvet M, Kleinberger G, Araque Caballero M, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8:466–76.
pubmed: 26941262
pmcid: 5120370
doi: 10.15252/emmm.201506123
Brosseron F, Traschütz A, Widmann CN, Kummer MP, Tacik P, Santarelli F, Jessen F, Heneka MT. Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease. Alzheimers Res Ther. 2018;10:25.
pubmed: 29482610
pmcid: 5828084
doi: 10.1186/s13195-018-0353-3
Henjum K, Almdahl IS, Årskog V, Minthon L, Hansson O, Fladby T, Nilsson LN. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease. Alzheimers Res Ther. 2016;8:17.
pubmed: 27121148
pmcid: 4848774
doi: 10.1186/s13195-016-0182-1
Gispert JD, Suárez-Calvet M, Monté GC, Tucholka A, Falcon C, Rojas S, Rami L, Sánchez-Valle R, Lladó A, Kleinberger G, et al. Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer’s disease. Alzheimers Dement. 2016;12:1259–72.
pubmed: 27423963
doi: 10.1016/j.jalz.2016.06.005
Suárez-Calvet M, Araque Caballero M, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C. Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8:369ra178.
pubmed: 27974666
pmcid: 5385711
doi: 10.1126/scitranslmed.aag1767
Ma LZ, Tan L, Bi YL, Shen XN, Xu W, Ma YH, Li HQ, Dong Q, Yu JT. Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study. Mol Neurodegener. 2020;15:25.
pubmed: 32276587
pmcid: 7149923
doi: 10.1186/s13024-020-00374-8
Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Schlepckow K, Araque Caballero M, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, et al. Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Mol Neurodegener. 2019;14:1.
pubmed: 30630532
pmcid: 6327425
doi: 10.1186/s13024-018-0301-5
Schmitz TW, Soreq H, Poirier J, Spreng RN. Longitudinal basal forebrain degeneration interacts with TREM2/C3 biomarkers of inflammation in presymptomatic Alzheimer’s disease. J Neurosci. 2020;40:1931–42.
pubmed: 31915256
pmcid: 7046458
doi: 10.1523/JNEUROSCI.1184-19.2019
Winfree RL, Dumitrescu L, Blennow K, Zetterberg H, Gifford KA, Pechman KR, Jefferson AL, Hohman TJ. Biological correlates of elevated soluble TREM2 in cerebrospinal fluid. Neurobiol Aging. 2022;118:88–98.
pubmed: 35908327
pmcid: 9707345
doi: 10.1016/j.neurobiolaging.2022.06.013
Edwin TH, Henjum K, Nilsson LNG, Watne LO, Persson K, Eldholm RS, Saltvedt I, Halaas NB, Selbæk G, Engedal K, et al. A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer’s disease. Alzheimers Dement (Amst). 2020;12: e12128.
pubmed: 33313376
Morenas-Rodríguez E, Li Y, Nuscher B, Franzmeier N, Xiong C, Suárez-Calvet M, Fagan AM, Schultz S, Gordon BA, Benzinger TLS, et al. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer’s disease: a longitudinal observational study. Lancet Neurol. 2022;21:329–41.
pubmed: 35305339
pmcid: 8926925
doi: 10.1016/S1474-4422(22)00027-8
Hu N, Tan MS, Yu JT, Sun L, Tan L, Wang YL, Jiang T, Tan L. Increased expression of TREM2 in peripheral blood of Alzheimer’s disease patients. J Alzheimers Dis. 2014;38:497–501.
pubmed: 24002183
doi: 10.3233/JAD-130854
Tan YJ, Ng ASL, Vipin A, Lim JKW, Chander RJ, Ji F, Qiu Y, Ting SKS, Hameed S, Lee TS, et al. Higher peripheral TREM2 mRNA levels relate to cognitive deficits and hippocampal atrophy in Alzheimer’s disease and amnestic mild cognitive impairment. J Alzheimers Dis. 2017;58:413–23.
pubmed: 28453482
doi: 10.3233/JAD-161277
Mori Y, Yoshino Y, Ochi S, Yamazaki K, Kawabe K, Abe M, Kitano T, Ozaki Y, Yoshida T, Numata S, et al. TREM2 mRNA expression in leukocytes is increased in Alzheimer’s disease and schizophrenia. PLoS ONE. 2015;10: e0136835.
pubmed: 26332043
pmcid: 4557831
doi: 10.1371/journal.pone.0136835
Casati M, Ferri E, Gussago C, Mazzola P, Abbate C, Bellelli G, Mari D, Cesari M, Arosio B. Increased expression of TREM2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer’s disease. Eur J Neurol. 2018;25:805–10.
pubmed: 29377401
doi: 10.1111/ene.13583
Guven G, Bilgic B, Samanci B, Gurvit H, Hanagasi H, Donmez C, Aslan R, Lohmann E, Erginel-Unaltuna N. Peripheral TREM2 mRNA levels in early and late-onset Alzheimer disease’s patients. Mol Biol Rep. 2020;47:5903–9.
pubmed: 32681391
doi: 10.1007/s11033-020-05661-7
Llorens F, Thüne K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, Kovatsi E, Pleschka C, Garcia-Esparcia P, Schmitz M, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017;12:83.
pubmed: 29126445
pmcid: 5681777
doi: 10.1186/s13024-017-0226-4
Bonneh-Barkay D, Wang G, Starkey A, Hamilton RL, Wiley CA. In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation. 2010;7:34.
pubmed: 20540736
pmcid: 2892443
doi: 10.1186/1742-2094-7-34
Baldacci F, Lista S, Cavedo E, Bonuccelli U, Hampel H. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases. Expert Rev Proteomics. 2017;14:285–99.
pubmed: 28281838
doi: 10.1080/14789450.2017.1304217
Arranz AM, De Strooper B. The role of astroglia in Alzheimer’s disease: pathophysiology and clinical implications. Lancet Neurol. 2019;18:406–14.
pubmed: 30795987
doi: 10.1016/S1474-4422(18)30490-3
Stephenson J, Nutma E, van der Valk P, Amor S. Inflammation in CNS neurodegenerative diseases. Immunology. 2018;154:204–19.
pubmed: 29513402
pmcid: 5980185
doi: 10.1111/imm.12922
Baldacci F, Lista S, Palermo G, Giorgi FS, Vergallo A, Hampel H. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. Expert Rev Proteomics. 2019;16:593–600.
pubmed: 31195846
doi: 10.1080/14789450.2019.1628643
Antonell A, Mansilla A, Rami L, Lladó A, Iranzo A, Olives J, Balasa M, Sánchez-Valle R, Molinuevo JL. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer’s disease. J Alzheimers Dis. 2014;42:901–8.
pubmed: 25024322
doi: 10.3233/JAD-140624
Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C, Scheltens P, van der Flier WM, Morris JC, Holtzman DM, Fagan AM. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort. Alzheimers Res Ther. 2015;7:59.
pubmed: 26383836
pmcid: 4574487
doi: 10.1186/s13195-015-0142-1
Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry. 2010;68:903–12.
pubmed: 21035623
pmcid: 3011944
doi: 10.1016/j.biopsych.2010.08.025
Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER, et al. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer’s disease continuum in the BIOMARKAPD study. Alzheimers Dement. 2019;15:742–53.
pubmed: 30967340
doi: 10.1016/j.jalz.2019.01.015
Baldacci F, Toschi N, Lista S, Zetterberg H, Blennow K, Kilimann I, Teipel S, Cavedo E, Dos Santos AM, Epelbaum S, et al. Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer’s disease. Alzheimers Dement. 2017;13:993–1003.
pubmed: 28263742
doi: 10.1016/j.jalz.2017.01.021
Paterson RW, Toombs J, Slattery CF, Nicholas JM, Andreasson U, Magdalinou NK, Blennow K, Warren JD, Mummery CJ, Rossor MN, et al. Dissecting IWG-2 typical and atypical Alzheimer’s disease: insights from cerebrospinal fluid analysis. J Neurol. 2015;262:2722–30.
pubmed: 26410752
doi: 10.1007/s00415-015-7904-3
Choi J, Lee HW, Suk K. Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer’s disease. J Neurol. 2011;258:2181–5.
pubmed: 21562723
doi: 10.1007/s00415-011-6087-9
Vergallo A, Lista S, Lemercier P, Chiesa PA, Zetterberg H, Blennow K, Potier MC, Habert MO, Baldacci F, Cavedo E, et al. Association of plasma YKL-40 with brain amyloid-β levels, memory performance, and sex in subjective memory complainers. Neurobiol Aging. 2020;96:22–32.
pubmed: 32920471
doi: 10.1016/j.neurobiolaging.2020.07.009
Grewal R, Haghighi M, Huang S, Smith AG, Cao C, Lin X, Lee DC, Teten N, Hill AM, Selenica MB. Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients. Alzheimers Res Ther. 2016;8:43.
pubmed: 27756387
pmcid: 5067885
doi: 10.1186/s13195-016-0211-0
Patani R, Hardingham GE, Liddelow SA. Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration. Nat Rev Neurol. 2023;19:395–409.
pubmed: 37308616
doi: 10.1038/s41582-023-00822-1
Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015;32:121–30.
pubmed: 25726916
doi: 10.1016/j.ceb.2015.02.004
Garwood CJ, Ratcliffe LE, Simpson JE, Heath PR, Ince PG, Wharton SB. Review: astrocytes in Alzheimer’s disease and other age-associated dementias: a supporting player with a central role. Neuropathol Appl Neurobiol. 2017;43:281–98.
pubmed: 27442752
doi: 10.1111/nan.12338
Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B, Nordberg A. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med. 2012;53:37–46.
pubmed: 22213821
doi: 10.2967/jnumed.110.087031
Muramori F, Kobayashi K, Nakamura I. A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer’s disease, normal controls and non-Alzheimer neuropsychiatric diseases. Psychiatry Clin Neurosci. 1998;52:593–9.
pubmed: 9895207
doi: 10.1111/j.1440-1819.1998.tb02706.x
Ishiki A, Kamada M, Kawamura Y, Terao C, Shimoda F, Tomita N, Arai H, Furukawa K. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer’s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem. 2016;136:258–61.
pubmed: 26485083
doi: 10.1111/jnc.13399
Elahi FM, Casaletto KB, La Joie R, Walters SM, Harvey D, Wolf A, Edwards L, Rivera-Contreras W, Karydas A, Cobigo Y, et al. Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer’s disease. Alzheimers Dement. 2020;16:681–95.
pubmed: 31879236
doi: 10.1016/j.jalz.2019.09.004
Oeckl P, Halbgebauer S, Anderl-Straub S, Steinacker P, Huss AM, Neugebauer H, von Arnim CAF, Diehl-Schmid J, Grimmer T, Kornhuber J, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67:481–8.
pubmed: 30594925
doi: 10.3233/JAD-180325
Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, Zwan MD, Verfaillie SCJ, Ossenkoppele R, Barkhof F, et al. Combination of plasma amyloid beta((1–42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020;12:118.
pubmed: 32988409
pmcid: 7523295
doi: 10.1186/s13195-020-00682-7
Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, Verberk IMW, Dave P, Taddei K, Sohrabi HR, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Transl Psychiatry. 2021;11:27.
pubmed: 33431793
pmcid: 7801513
doi: 10.1038/s41398-020-01137-1
Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N, Hansson O. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021;13:68.
pubmed: 33773595
pmcid: 8005231
doi: 10.1186/s13195-021-00804-9
O’Connor A, Abel E, Benedet AL, Poole T, Ashton N, Weston PSJ, Heslegrave AJ, Ryan N, Barker S, Polke JM, et al. Plasma GFAP in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study. J Neurol Neurosurg Psychiatry. 2023;94:90–2.
pubmed: 35948396
doi: 10.1136/jnnp-2022-329663
Silva-Spínola A, Lima M, Leitão MJ, Bernardes C, Durães J, Duro D, Tábuas-Pereira M, Santana I, Baldeiras I. Blood biomarkers in mild cognitive impairment patients: relationship between analytes and progression to Alzheimer disease dementia. Eur J Neurol. 2023;30:1565–73.
pubmed: 36880887
doi: 10.1111/ene.15762
Chatterjee P, Pedrini S, Ashton NJ, Tegg M, Goozee K, Singh AK, Karikari TK, Simrén J, Vanmechelen E, Armstrong NJ, et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer’s disease. Alzheimers Dement. 2022;18:1141–54.
pubmed: 34494715
doi: 10.1002/alz.12447
Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, Zetterberg H, Stomrud E, Ashton NJ, Blennow K, Hansson O. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease. Brain. 2021;144:3505–16.
pubmed: 34259835
pmcid: 8677538
doi: 10.1093/brain/awab223
Bellaver B, Povala G, Ferreira PCL, Ferrari-Souza JP, Leffa DT, Lussier FZ, Benedet AL, Ashton NJ, Triana-Baltzer G, Kolb HC, et al. Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease. Nat Med. 2023;29:1775–81.
pubmed: 37248300
pmcid: 10353939
doi: 10.1038/s41591-023-02380-x
Verberk IMW, Laarhuis MB, van den Bosch KA, Ebenau JL, van Leeuwenstijn M, Prins ND, Scheltens P, Teunissen CE, van der Flier WM. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev. 2021;2:e87–95.
pubmed: 36098162
doi: 10.1016/S2666-7568(20)30061-1
Stocker H, Beyer L, Perna L, Rujescu D, Holleczek B, Beyreuther K, Stockmann J, Schöttker B, Gerwert K, Brenner H. Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer’s disease risk: results from a prospective cohort followed over 17 years. Alzheimers Dement. 2023;19:25–35.
pubmed: 35234335
doi: 10.1002/alz.12614
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Münch AE, Chung WS, Peterson TC, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–7.
pubmed: 28099414
pmcid: 5404890
doi: 10.1038/nature21029
Cronjé HT, Liu X, Odden MC, Moseholm KF, Seshadri S, Satizabal CL, Lopez OL, Bis JC, Djoussé L, Fohner AE, et al. Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: the cardiovascular health study. Alzheimers Dement. 2023.
Varma VR, An Y, Kac PR, Bilgel M, Moghekar A, Loeffler T, Amschl D, Troncoso J, Blennow K, Zetterberg H, et al. Longitudinal progression of blood biomarkers reveals a key role of astrocyte reactivity in preclinical Alzheimer’s disease. medRxiv 2024.
Kapoor M, Chinnathambi S. TGF-β1 signalling in Alzheimer’s pathology and cytoskeletal reorganization: a specialized Tau perspective. J Neuroinflammation. 2023;20:72.
pubmed: 36915196
pmcid: 10012507
doi: 10.1186/s12974-023-02751-8
Caraci F, Spampinato SF, Morgese MG, Tascedda F, Salluzzo MG, Giambirtone MC, Caruso G, Munafò A, Torrisi SA, Leggio GM, et al. Neurobiological links between depression and AD: the role of TGF-β1 signaling as a new pharmacological target. Pharmacol Res. 2018;130:374–84.
pubmed: 29438781
doi: 10.1016/j.phrs.2018.02.007
Tichauer JE, von Bernhardi R. Transforming growth factor-β stimulates β amyloid uptake by microglia through Smad3-dependent mechanisms. J Neurosci Res. 2012;90:1970–80.
pubmed: 22715062
doi: 10.1002/jnr.23082
Caraci F, Gulisano W, Guida CA, Impellizzeri AA, Drago F, Puzzo D, Palmeri A. A key role for TGF-β1 in hippocampal synaptic plasticity and memory. Sci Rep. 2015;5:11252.
pubmed: 26059637
pmcid: 4462026
doi: 10.1038/srep11252
Caraci F, Spampinato S, Sortino MA, Bosco P, Battaglia G, Bruno V, Drago F, Nicoletti F, Copani A. Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for neuroprotection. Cell Tissue Res. 2012;347:291–301.
pubmed: 21879289
doi: 10.1007/s00441-011-1230-6
Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, Lin AH, Crews L, Tremblay P, Mathews P, et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer’s pathology. J Clin Invest. 2006;116:3060–9.
pubmed: 17080199
pmcid: 1626127
doi: 10.1172/JCI27341
Juraskova B, Andrys C, Holmerova I, Solichova D, Hrnciarikova D, Vankova H, Vasatko T, Krejsek J. Transforming growth factor beta and soluble endoglin in the healthy senior and in Alzheimer’s disease patients. J Nutr Health Aging. 2010;14:758–61.
pubmed: 21085906
doi: 10.1007/s12603-010-0325-1
Luppi C, Fioravanti M, Bertolini B, Inguscio M, Grugnetti A, Guerriero F, Rovelli C, Cantoni F, Guagnano P, Marazzi E, et al. Growth factors decrease in subjects with mild to moderate Alzheimer’s disease (AD): potential correction with dehydroepiandrosterone-sulphate (DHEAS). Arch Gerontol Geriatr. 2009;49(Suppl 1):173–84.
pubmed: 19836631
doi: 10.1016/j.archger.2009.09.027
Wyss-Coray T. Tgf-Beta pathway as a potential target in neurodegeneration and Alzheimer’s. Curr Alzheimer Res. 2006;3:191–5.
pubmed: 16842094
doi: 10.2174/156720506777632916
Tarkowski E, Issa R, Sjögren M, Wallin A, Blennow K, Tarkowski A, Kumar P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer’s disease and vascular dementia. Neurobiol Aging. 2002;23:237–43.
pubmed: 11804709
doi: 10.1016/S0197-4580(01)00285-8
Mocali A, Cedrola S, Della Malva N, Bontempelli M, Mitidieri VA, Bavazzano A, Comolli R, Paoletti F, La Porta CA. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Exp Gerontol. 2004;39:1555–61.
pubmed: 15501026
doi: 10.1016/j.exger.2004.07.007
Gogishvili D, Vromen EM, Koppes-den Hertog S, Lemstra AW, Pijnenburg YAL, Visser PJ, Tijms BM, Del Campo M, Abeln S, Teunissen CE, Vermunt L. Discovery of novel CSF biomarkers to predict progression in dementia using machine learning. Sci Rep. 2023;13:6531.
pubmed: 37085545
pmcid: 10121677
doi: 10.1038/s41598-023-33045-x
Bosco P, Ferri R, Salluzzo MG, Castellano S, Signorelli M, Nicoletti F, Nuovo SD, Drago F, Caraci F. Role of the transforming-growth-factor-β1 gene in late-onset Alzheimer’s disease: implications for the treatment. Curr Genomics. 2013;14:147–56.
pubmed: 24082824
pmcid: 3637679
doi: 10.2174/1389202911314020007
Arosio B, Bergamaschini L, Galimberti L, La Porta C, Zanetti M, Calabresi C, Scarpini E, Annoni G, Vergani C. +10 T/C polymorphisms in the gene of transforming growth factor-beta1 are associated with neurodegeneration and its clinical evolution. Mech Ageing Dev. 2007;128:553–7.
pubmed: 17889927
doi: 10.1016/j.mad.2007.07.006
Caraci F, Bosco P, Signorelli M, Spada RS, Cosentino FI, Toscano G, Bonforte C, Muratore S, Prestianni G, Panerai S, et al. The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer’s disease and is associated with AD-related depression. Eur Neuropsychopharmacol. 2012;22:281–9.
pubmed: 21924590
doi: 10.1016/j.euroneuro.2011.08.006
Fraga VG, Guimarães HC, Lara VP, Teixeira AL, Barbosa MT, Carvalho MG, Caramelli P, Gomes KB. TGF-β1 Codon 10 T>C polymorphism influences short-term functional and cognitive decline in healthy oldest-old individuals: the Pietà study. J Alzheimers Dis. 2015;48:1077–81.
pubmed: 26402106
doi: 10.3233/JAD-150397
Estrada LD, Oliveira-Cruz L, Cabrera D. Transforming growth factor beta type I role in neurodegeneration: implications for Alzheimer’s disease. Curr Protein Pept Sci. 2018;19:1180–8.
pubmed: 29189146
doi: 10.2174/1389203719666171129094937
Yin Z, Rosenzweig N, Kleemann KL, Zhang X, Brandão W, Margeta MA, Schroeder C, Sivanathan KN, Silveira S, Gauthier C, et al. APOE4 impairs the microglial response in Alzheimer’s disease by inducing TGFβ-mediated checkpoints. Nat Immunol. 2023;24:1839–53.
pubmed: 37749326
doi: 10.1038/s41590-023-01627-6
Brosseron F, Maass A, Kleineidam L, Ravichandran KA, González PG, McManus RM, Ising C, Santarelli F, Kolbe CC, Häsler LM, et al. Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer’s disease. Neuron. 2022;110:1009-1022.e1004.
pubmed: 34995486
doi: 10.1016/j.neuron.2021.12.016
Popp J, Oikonomidi A, Tautvydaitė D, Dayon L, Bacher M, Migliavacca E, Henry H, Kirkland R, Severin I, Wojcik J, Bowman GL. Markers of neuroinflammation associated with Alzheimer’s disease pathology in older adults. Brain Behav Immun. 2017;62:203–11.
pubmed: 28161476
doi: 10.1016/j.bbi.2017.01.020
Morgan AR, Touchard S, Leckey C, O’Hagan C, Nevado-Holgado AJ, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, et al. Inflammatory biomarkers in Alzheimer’s disease plasma. Alzheimers Dement. 2019;15:776–87.
pubmed: 31047856
doi: 10.1016/j.jalz.2019.03.007
Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry. 2010;68:930–41.
pubmed: 20692646
doi: 10.1016/j.biopsych.2010.06.012
Lai KSP, Liu CS, Rau A, Lanctôt KL, Köhler CA, Pakosh M, Carvalho AF, Herrmann N. Peripheral inflammatory markers in Alzheimer’s disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry. 2017;88:876–82.
pubmed: 28794151
doi: 10.1136/jnnp-2017-316201
Shen XN, Niu LD, Wang YJ, Cao XP, Liu Q, Tan L, Zhang C, Yu JT. Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies. J Neurol Neurosurg Psychiatry. 2019;90:590–8.
pubmed: 30630955
doi: 10.1136/jnnp-2018-319148
Su C, Zhao K, Xia H, Xu Y. Peripheral inflammatory biomarkers in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis. Psychogeriatrics. 2019;19:300–9.
pubmed: 30790387
doi: 10.1111/psyg.12403
Darweesh SKL, Wolters FJ, Ikram MA, de Wolf F, Bos D, Hofman A. Inflammatory markers and the risk of dementia and Alzheimer’s disease: a meta-analysis. Alzheimers Dement. 2018;14:1450–9.
pubmed: 29605221
doi: 10.1016/j.jalz.2018.02.014
Brosseron F, Maass A, Kleineidam L, Ravichandran KA, Kolbe CC, Wolfsgruber S, Santarelli F, Häsler LM, McManus R, Ising C, et al. Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer’s disease: results from the DELCODE study. Alzheimers Res Ther. 2023;15:13.
pubmed: 36631909
pmcid: 9835320
doi: 10.1186/s13195-022-01118-0
Liu P, Wang Y, Sun Y, Peng G. Neuroinflammation as a potential therapeutic target in Alzheimer’s disease. Clin Interv Aging. 2022;17:665–74.
pubmed: 35520949
pmcid: 9064449
doi: 10.2147/CIA.S357558
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388:9–21.
pubmed: 36449413
doi: 10.1056/NEJMoa2212948
Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, Collins EC, Sims JR, Mintun MA. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79:1250–9.
pubmed: 36251300
pmcid: 9577883
doi: 10.1001/jamaneurol.2022.3392
O’Bryant SE, Zhang F, Johnson LA, Hall J, Edwards M, Grammas P, Oh E, Lyketsos CG, Rissman RA. A precision medicine model for targeted NSAID therapy in Alzheimer’s disease. J Alzheimers Dis. 2018;66:97–104.
pubmed: 30198872
pmcid: 6428063
doi: 10.3233/JAD-180619
Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384:1691–704.
pubmed: 33720637
doi: 10.1056/NEJMoa2100708
Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, Dhadda S, Sethuraman G, Kramer LD, Swanson CJ, et al. The AHEAD 3–45 study: design of a prevention trial for Alzheimer’s disease. Alzheimers Dement. 2023;19:1227–33.
pubmed: 35971310
doi: 10.1002/alz.12748
Beyer L, Stocker H, Rujescu D, Holleczek B, Stockmann J, Nabers A, Brenner H, Gerwert K. Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer’s disease diagnosis within 17 years. Alzheimers Dement. 2022;19:1020.
doi: 10.1002/alz.12745
Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414–24.
pubmed: 37280110
pmcid: 10629981
doi: 10.1093/brain/awad188
Love S, Miners JS. Cerebrovascular disease in ageing and Alzheimer’s disease. Acta Neuropathol. 2016;131:645–58.
pubmed: 26711459
doi: 10.1007/s00401-015-1522-0
Janelidze S, Mattsson N, Stomrud E, Lindberg O, Palmqvist S, Zetterberg H, Blennow K, Hansson O. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018;91:e867–77.
pubmed: 30054439
pmcid: 6133624
doi: 10.1212/WNL.0000000000006082
Group F-NBW: In BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD) Bethesda (MD): Food and Drug Administration (US) National Institutes of Health (US); 2016.
Sun N, Victor MB, Park YP, Xiong X, Scannail AN, Leary N, Prosper S, Viswanathan S, Luna X, Boix CA, et al. Human microglial state dynamics in Alzheimer’s disease progression. Cell. 2023;186:4386-4403.e4329.
pubmed: 37774678
doi: 10.1016/j.cell.2023.08.037
Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, Rongve A, Børte S, Winsvold BS, Drange OK, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease. Nat Genet. 2021;53:1276–82.
pubmed: 34493870
pmcid: 10243600
doi: 10.1038/s41588-021-00921-z
Griciuc A, Tanzi RE. The role of innate immune genes in Alzheimer’s disease. Curr Opin Neurol. 2021;34:228–36.
pubmed: 33560670
pmcid: 7954128
doi: 10.1097/WCO.0000000000000911
Wang S, Mustafa M, Yuede CM, Salazar SV, Kong P, Long H, Ward M, Siddiqui O, Paul R, Gilfillan S, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J Exp Med. 2020;217:e20200785.
pubmed: 32579671
pmcid: 7478730
doi: 10.1084/jem.20200785
Yeo IJ, Lee CK, Han SB, Yun J, Hong JT. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol Ther. 2019;203: 107394.
pubmed: 31356910
doi: 10.1016/j.pharmthera.2019.107394
Alcolea D, Carmona-Iragui M, Suárez-Calvet M, Sánchez-Saudinós MB, Sala I, Antón-Aguirre S, Blesa R, Clarimón J, Fortea J, Lleó A. Relationship between β-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer’s disease. J Alzheimers Dis. 2014;42:157–67.
pubmed: 24820015
doi: 10.3233/JAD-140240
Wilczyńska K, Maciejczyk M, Zalewska A, Waszkiewicz N. Serum amyloid biomarkers, tau protein and YKL-40 utility in detection, differential diagnosing, and monitoring of dementia. Front Psychiatry. 2021;12: 725511.
pubmed: 34589009
pmcid: 8473887
doi: 10.3389/fpsyt.2021.725511
Shue F, White LJ, Hendrix R, Ulrich J, Henson RL, Knight W, Martens YA, Wang N, Roy B, Starling SC, et al. CSF biomarkers of immune activation and Alzheimer’s disease for predicting cognitive impairment risk in the elderly. Sci Adv. 2024;10:eadk3674.
pubmed: 38569027
pmcid: 10990276
doi: 10.1126/sciadv.adk3674
Ewers M, Franzmeier N, Suárez-Calvet M, Morenas-Rodriguez E, Caballero MAA, Kleinberger G, Piccio L, Cruchaga C, Deming Y, Dichgans M, et al. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease. Sci Transl Med. 2019; 11.
Zhao A, Jiao Y, Ye G, Kang W, Tan L, Li Y, Deng Y, Liu J. Soluble TREM2 levels associate with conversion from mild cognitive impairment to Alzheimer’s disease. J Clin Invest. 2022; 132.
Bieger A, Rocha A, Bellaver B, Machado L, Da Ros L, Borelli WV, Therriault J, Macedo AC, Pascoal TA, Gauthier S, et al. Neuroinflammation biomarkers in the AT(N) framework across the Alzheimer’s disease continuum. J Prev Alzheimers Dis. 2023;10:401–17.
pubmed: 37357281
Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D’Anna L, Huss A, Oeckl P, Ludolph AC, Kuhle J, Petzold A, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18:158–72.
pubmed: 35115728
doi: 10.1038/s41582-021-00616-3
Wang Q, Xu Y, Qi C, Liu A, Zhao Y. Association study of serum soluble TREM2 with vascular dementia in Chinese Han population. Int J Neurosci. 2020;130:708–12.
pubmed: 31847649
doi: 10.1080/00207454.2019.1702548
Limberger C, Zimmer ER. Blood GFAP reflects astrocyte reactivity to Alzheimer’s pathology in post-mortem brain tissue. Brain. 2024;147:1598–600.
pubmed: 38634672
doi: 10.1093/brain/awae104
Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O’Bryant S, Shaw LM, Cho M, et al. Blood-based biomarkers for Alzheimer’s disease: current state and future use in a transformed global healthcare landscape. Neuron. 2023;111:2781–99.
pubmed: 37295421
doi: 10.1016/j.neuron.2023.05.017
Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, Salloway S, Sperling R, Zetterberg H, Teunissen CE. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement. 2022;18:2669–86.
pubmed: 35908251
doi: 10.1002/alz.12756
Tybirk L, Hviid CVB, Knudsen CS, Parkner T. Serum GFAP—reference interval and preanalytical properties in Danish adults. Clin Chem Lab Med. 2022;60:1830–8.
pubmed: 36067832
doi: 10.1515/cclm-2022-0646
Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, Karikari TK, Hourregue C, Cognat E, Dumurgier J, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78:1471–83.
pubmed: 34661615
doi: 10.1001/jamaneurol.2021.3671
Olsson B, Hertze J, Lautner R, Zetterberg H, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, et al. Microglial markers are elevated in the prodromal phase of Alzheimer’s disease and vascular dementia. J Alzheimers Dis. 2013;33:45–53.
pubmed: 22890100
doi: 10.3233/JAD-2012-120787
Yakoub Y, Ashton NJ, Strikwerda-Brown C, Montoliu-Gaya L, Karikari TK, Kac PR, Gonzalez-Ortiz F, Gallego-Rudolf J, Meyer PF, St-Onge F, et al. Longitudinal blood biomarker trajectories in preclinical Alzheimer’s disease. Alzheimers Dement. 2023;19:5620.
pubmed: 37294682
doi: 10.1002/alz.13318
Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003;61:76–80.
pubmed: 12847160
doi: 10.1212/01.WNL.0000073620.42047.D7
Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, Benjamin EJ, Au R, Kiel DP, Wolf PA, Seshadri S. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology. 2007;68:1902–8.
pubmed: 17536046
doi: 10.1212/01.wnl.0000263217.36439.da
Caldwell JZK, Kinney JW, Ritter A, Salazar A, Wong CG, Cordes D, Slavich GM. Inflammatory cytokine levels implicated in Alzheimer’s disease moderate the effects of sex on verbal memory performance. Brain Behav Immun. 2021;95:27–35.
pubmed: 33301871
doi: 10.1016/j.bbi.2020.12.001